Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.8M | $16.7M | $19.0M | $17.9M | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Revenue growth | — | 29.9% | 13.9% | -5.5% | 3.9% | -32.2% | 5.1% | -4.0% | 12.2% | 36.7% |
| Gross profit | $5.67M | $7.31M | $8.88M | $8.12M | $6.56M | $3.99M | $4.48M | $4.75M | $5.46M | $7.42M |
| Gross margin | 44.2% | 43.9% | 46.8% | 45.3% | 35.2% | 31.6% | 33.7% | 37.3% | 38.2% | 38.0% |
| Operating income | -$13.0M | -$14.2M | -$11.3M | -$7.39M | -$3.45M | -$5.89M | -$4.57M | -$4.70M | -$3.71M | -$2.46M |
| Operating margin | -101.2% | -85.2% | -59.3% | -41.2% | -18.5% | -46.6% | -34.4% | -36.9% | -26.0% | -12.6% |
| Net income | $9.27M | -$14.3M | -$11.8M | -$3.31M | -$3.95M | -$5.09M | -$5.15M | -$4.83M | -$3.46M | -$3.17M |
| Net margin | 72.3% | -86.0% | -62.2% | -18.5% | -21.2% | -40.3% | -38.8% | -38.0% | -24.2% | -16.3% |
| EPS (diluted) | $2.20 | -$28.49 | -$12.77 | -$2.24 | -$1.97 | -$1.92 | -$1.52 | -$10.63 | -$2.79 | -$1.89 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.17M | -$12.4M | -$11.7M | -$4.59M | -$3.38M | -$4.25M | -$6.15M | -$2.40M | -$88.0K | -$3.93M |
| Capital expenditures | $394K | $187K | $100K | $206K | $179K | $137K | $269K | $2.00K | $80.0K | $192K |
| Free cash flow | -$8.56M | -$12.6M | -$11.8M | -$4.80M | -$3.56M | -$4.38M | -$6.42M | -$2.40M | -$168K | -$4.13M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.5M | $10.1M | $3.69M | $3.69M | $4.22M | $7.40M | $3.82M | $3.13M | $5.37M | $2.40M |
| Total assets | $25.5M | $19.2M | $14.4M | $14.6M | $15.0M | $18.8M | $16.2M | $14.7M | $13.7M | $14.0M |
| Total liabilities | $4.03M | $3.88M | $3.96M | $8.94M | $9.62M | $10.1M | $8.25M | $8.60M | $9.28M | $10.9M |
| Long-term debt | $45.0K | $32.0K | $12.0K | $0.00 | $1.31M | $0.00 | — | — | — | — |
| Shareholders' equity | $21.4M | $15.3M | $7.77M | $5.62M | $5.36M | $8.70M | $7.98M | $6.14M | $4.41M | $3.10M |
| Retained earnings | -$143M | -$157M | -$169M | -$175M | -$179M | -$184M | -$190M | -$194M | -$198M | -$201M |
| Shares (wtd avg diluted) | 4.29M | 686K | 1.32M | 1.78M | 2.09M | 2.65B | 3.39M | 455K | 1.24M | 1.68M |
Every figure is extracted from Sonoma Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.